ONASEMNOGENE ABEPARVOVEC
onasemnogene abeparvovec 20 trillion vector genomes/mL injection, 6 x 8.3 mL vials
ONASEMNOGENE ABEPARVOVEC (12973T)
12973T
Manner of administration:Injection
Restriction
Indication: Spinal muscular atrophy (SMA)
Treatment phase: Use in a patient untreated with disease modifying therapies for this condition
Restriction
Indication: Spinal muscular atrophy (SMA)
Treatment phase: Use occurring after treatment with at least one disease modifying therapy for this
condition (i.e. switching from nusinersen/risdiplam to onasemnogene abeparvovec)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 0 | DPMQ: $2,527,773.87 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Zolgensma | |||||